The report says Q2 EBITDA/APAT were 23%/5% above estimates on pricing-led revenue growth, and maintains ADD with a target price of INR 201.
Read this note →NOCIL Limited
NSE NOCIL BSE 500730 INE163A01018
0 filings · 0 analysed
138.05
-19.34%
over 1 year
-
HSIE Results Daily 31 Oct 26 HSIE
The report says Q2 EBITDA/APAT were 23%/5% above estimates on pricing-led revenue growth, and maintains ADD with a target price of INR 201.
-
Chemicals Q2FY27 Results Preview HSIE
The report expects EBITDA margin to fall 349.5bps QoQ to 7.5% despite 20% YoY revenue growth.
Prices from Yahoo Finance, NSE close, delayed — indicative only, not for dealing. Solid markers sit on the exchange's own timestamp.
Targets, and what happened next
What each house published, and where the price has gone since. Orivam issues no calls of its own and takes no view on these.
| House | Published | Call | Entry | Target | Now | Progress | Standing |
|---|---|---|---|---|---|---|---|
| HDFC Securities | 14 Oct 2026, 15:45 | long | 164.91 | 201.00 | 135.68 | -81% | open by 2027-10-14 |
Deadlines: 0 stated by the house, the rest set by Orivam’s convention — ten trading days for a technical call, twelve months for a price target. A target with no date cannot be judged, so one has to be chosen.
What the desks said
The report expects EBITDA margin to fall 349.5bps QoQ to 7.5% despite 20% YoY revenue growth.
Read this note →Announcement timeline
No filings stored for this company yet.
Never miss the next one.
Orivam emails what the research desks published each trading morning, attributed and linked to the original notes. Free.
Get the daily brief